title: Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia.
abstract: Molecular genetic techniques permit sensitive assessment of host hematopoiesis after marrow transplantation for thalassemia. Information on this persistence and the cell lines in which it occurs may permit therapeutic intervention in patients at high risk for rejection and/or relapse. The objective of this study, therefore, was to determine the evolution and cell line distribution of persistent mixed chimerism detected in 55 patients treated for beta thalassemia. Our findings indicated that rejection occurred in 20 patients, the host component disappeared in 20, and mixed chimerism without transfusion need persisted for 1 to 7 years in 15. In three patients with stable mixed chimerism for 4, 5, and 7 years, host hematopoiesis fluctuated between 25% and 75%. Despite this, donor pattern beta-globin chain synthesis maintained hemoglobin levels between 10 and 13.5 g/dL without transfusion. In these three patients, the polymerase chain reaction of the VNTR and the fluorescent in situ hybridization analysis revealed the coexistence of donor and host cells in the different peripheral blood cell subpopulations and precursors studied (CD2+, CD4+, CD8+, and CD19+ granulocytes; glycophorin-A+, erythroid burst-forming units, CD33+, granulocyte-macrophage colony-forming units). We found that rejection and disease recurrence occur in approximately one third of patients with early mixed chimerism. High levels of host type hematopoiesis can be present in patients not requiring transfusion.
authors.affiliation: Divisione Ematologica e Centro Trapianto di Midollo Osseo di Muraglia, Azienda Ospedaliera San Salvatore di Pesaro, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Andreani
authors.forename: M
authors.initials: M
authors.lastname: Manna
authors.forename: G
authors.initials: G
authors.lastname: Lucarelli
authors.forename: P
authors.initials: P
authors.lastname: Tonucci
authors.forename: F
authors.initials: F
authors.lastname: Agostinelli
authors.forename: M
authors.initials: M
authors.lastname: Ripalti
authors.forename: S
authors.initials: S
authors.lastname: Rapa
authors.forename: N
authors.initials: N
authors.lastname: Talevi
authors.forename: M
authors.initials: M
authors.lastname: Galimberti
authors.forename: S
authors.initials: S
authors.lastname: Nesci
mesh_terms: D000293:Adolescent; D000328:Adult; D001773:Blood Cells; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D016026:Bone Marrow Transplantation / Q000473:pathology*; D019070:Cell Lineage; D002470:Cell Survival; D002648:Child; D002675:Child, Preschool; D002678:Chimera; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D005500:Follow-Up Studies; D005914:Globins / Q000032:analysis / Q000235:genetics; D006085:Graft Survival; D006086:Graft vs Host Disease; D006412:Hematopoietic Stem Cells / Q000737:chemistry / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D008297:Male; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D012008:Recurrence; D013789:Thalassemia / Q000235:genetics / Q000473:pathology / Q000628:therapy*
chemical_list: D003520:Cyclophosphamide; D005914:Globins